385 results Stibbe advises Sistema JSFC Stibbe advises Lindsay Goldberg Advising Lindsay Goldberg on the acquisition of Plasticum Group. The acquisition fits well with Lindsay Goldberg's acquisition of Weener Plastic Packaging Group in Germany earlier in 2012. Stibbe advises Cymer Stibbe advises EPZ Stibbe advises Eni Stibbe assisted Eni s.p.a. in the EUR 157 million acquisition of Nuon Belgium NV, its subsidiary Nuon Wind Belgium NV and Nuon Power Generation Walloon NV from Vattenfall AB. Stibbe advises Nuclear Energy Research Centre Stibbe assisted the Nuclear Energy Research Centre (SCK-CEN) on the financing, construction, and licensing of its new experimental nuclear reactor Myrrha. Stibbe advises Eneco Advising and representing Eneco in relation to permitting of off shore wind farms in the Dutch part of the North Sea. Stibbe advises Belgian infrastructure funds Stibbe assisted Belgian infrastructure funds DG Infra, Inframan, DHAM and PMF (PMV) as subordinated lenders in the EUR 850 million project finance of the Northwind offshore wind power project. Stibbe advises Provinces of Flevoland and Friesland Advising governmental bodies, such as the provinces of Flevoland and Friesland in public law cases, such as EC law, subsidies and planning and environmental law issues. Stibbe advises global industrial company Stibbe advised a global industrial company on an overview of the minimal requirements and obligations as a company to comply with the European principles of duty of care regarding the presence of hazardhous substances in their product. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises Koepel Windenergie Advising and representing Koepel Windenergie on the permitting of the largest European on shore wind farm (450 Mw) in the Noordoostpolder. Stibbe advises Wavin Advising Wavin, the leading supplier of plastic pipe systems and solutions in Europe, in relation to the EUR 523 million public offer from Mexichem for the acquisition of all outstanding shares of Wavin. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises GDF and Nuon Advising and representing GDF Suez and Nuon Vattenfall on the environmental and nature impact permitting of the gas and coal fired power plants of Nuon Vattenfall (in Groningen) and GDF Suez (in Rotterdam). Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Pagination Previous page Page 18 Current page 19 Page 20 Page 21 Next page
Stibbe advises Lindsay Goldberg Advising Lindsay Goldberg on the acquisition of Plasticum Group. The acquisition fits well with Lindsay Goldberg's acquisition of Weener Plastic Packaging Group in Germany earlier in 2012.
Stibbe advises Eni Stibbe assisted Eni s.p.a. in the EUR 157 million acquisition of Nuon Belgium NV, its subsidiary Nuon Wind Belgium NV and Nuon Power Generation Walloon NV from Vattenfall AB.
Stibbe advises Nuclear Energy Research Centre Stibbe assisted the Nuclear Energy Research Centre (SCK-CEN) on the financing, construction, and licensing of its new experimental nuclear reactor Myrrha.
Stibbe advises Eneco Advising and representing Eneco in relation to permitting of off shore wind farms in the Dutch part of the North Sea.
Stibbe advises Belgian infrastructure funds Stibbe assisted Belgian infrastructure funds DG Infra, Inframan, DHAM and PMF (PMV) as subordinated lenders in the EUR 850 million project finance of the Northwind offshore wind power project.
Stibbe advises Provinces of Flevoland and Friesland Advising governmental bodies, such as the provinces of Flevoland and Friesland in public law cases, such as EC law, subsidies and planning and environmental law issues.
Stibbe advises global industrial company Stibbe advised a global industrial company on an overview of the minimal requirements and obligations as a company to comply with the European principles of duty of care regarding the presence of hazardhous substances in their product.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises Koepel Windenergie Advising and representing Koepel Windenergie on the permitting of the largest European on shore wind farm (450 Mw) in the Noordoostpolder.
Stibbe advises Wavin Advising Wavin, the leading supplier of plastic pipe systems and solutions in Europe, in relation to the EUR 523 million public offer from Mexichem for the acquisition of all outstanding shares of Wavin.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises GDF and Nuon Advising and representing GDF Suez and Nuon Vattenfall on the environmental and nature impact permitting of the gas and coal fired power plants of Nuon Vattenfall (in Groningen) and GDF Suez (in Rotterdam).
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.